CS
NRIX icon

Credit Suisse’s Nurix Therapeutics NRIX Stock Holding History

Credit Suisse’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-52,328
Closed -$411K – 3114
2023
Q3 		$411K Sell
52,328
-6,249
-11% -$57.1K ﹤0.01% 2784
2023
Q2 		$585K Buy
58,577
+31,177
+114% +$318K ﹤0.01% 2694
2023
Q1 		$243K Buy
27,400
+9
+0% +$94 ﹤0.01% 3061
2022
Q4 		$301K Sell
27,391
-1,459
-5% -$17.6K ﹤0.01% 3039
2022
Q3 		$376K Buy
28,850
+13,231
+85% +$209K ﹤0.01% 2964
2022
Q2 		$197K Buy
15,619
+1,145
+8% +$13K ﹤0.01% 3336
2022
Q1 		$203K Buy
14,474
+779
+6% +$13.8K ﹤0.01% 3369
2021
Q4 		$396K Sell
13,695
-3
-0% -$91 ﹤0.01% 3983
2021
Q3 		$411K Buy
13,698
+3,385
+33% +$104K ﹤0.01% 3933
2021
Q2 		$273K Buy
10,313
+487
+5% +$14.3K ﹤0.01% 4152
2021
Q1 		$306K Sell
9,826
-7,956
-45% -$301K ﹤0.01% 3987
2020
Q4 		$584K Buy
+17,782
New +$589K ﹤0.01% 3711

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Credit Suisse's NRIX Position: Q4 2023 in Review

Credit Suisse sold out of Nurix Therapeutics (NRIX) in Q4 2023, closing a stake of 52,328 shares — an estimated $411K sold.

Credit Suisse first reported a position in NRIX in Q4 2020 and held it in 12 quarters. The position peaked at $585K in Q2 2023. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • Credit Suisse reported no remaining Nurix Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 52,328 Nurix Therapeutics shares in Q4 2023, an estimated $411K.
  • Credit Suisse first reported a position in Nurix Therapeutics in Q4 2020 and held it in 12 quarters.
  • Credit Suisse's Nurix Therapeutics position peaked at $585K in Q2 2023.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.